ArticleDigestive diseases and sciences2015
Percutaneous Intraluminal Radiofrequency Ablation for Malignant Extrahepatic Biliary Obstruction: A Safe and Feasible Method.
Article in Digestive diseases and sciences, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 37 citations in OpenAlex.
- Endobiliary Radiofrequency Ablation for Hepato-Biliary Diseases: A Narrative Review.Diseases (Basel, Switzerland) · 2025Review
- Intraductal ablation therapy for malignant biliary obstruction.Langenbeck's archives of surgery · 2024Review
- Radiofrequency ablation in the management of primary hepatic and biliary tumors.World journal of gastrointestinal oncology · 2022Review
- Percutaneous endobiliary ablation of malignant biliary strictures with a novel temperature-controlled radiofrequency ablation device.Diagnostic and interventional radiology (Ankara, Turkey) · 2021Article
- Percutaneous intraductal radiofrequency ablation combined with biliary stent placement for treatment of malignant biliary obstruction.Abdominal radiology (New York) · 2020Article
- Ablative therapies for hepatic and biliary tumors: endohepatology coming of age.Translational gastroenterology and hepatology · 2020Review
- Intraductal temperature-controlled radiofrequency ablation in malignant hilar obstruction: a preliminary study in animals and initial human experience.Endoscopy international open · 2019Article
- Interventional radiofrequency ablation: A promising therapeutic modality in the management of malignant biliary and pancreatic duct obstruction.Journal of Cancer · 2018Article
- Article
- Review of endoscopic radiofrequency in biliopancreatic tumours with emphasis on clinical benefits, controversies and safety.World journal of gastroenterology · 2016Review
- Percutaneous intraductal radiofrequency ablation in the management of unresectable Bismuth types III and IV hilar cholangiocarcinoma.Oncotarget · 2016Article
- Observational
- Malignant Biliary Obstruction: Evidence for Best Practice.Gastroenterology research and practice · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroudThe Habib™ EndoHBP catheter is a novel bipolar radiofrequency catheter developed for intraluminal ablation to relieve malignant extrahepatic biliary obstruction. Clinical experience with its use is limited and scattered.
aimThe purpose of this study was to evaluate the clinical feasibility and safety of this technique.
methodsA single central retrospective analysis was performed with patients who underwent percutaneous intraluminal radiofrequency ablation (RFA) combined with biliary stenting for treatment of extrahepatic obstructive jaundice between September 2011 and May 2014. A Habib™ EndoHBP catheter was used for RFA. Clinical and telephonic follow-ups were carried out. Procedure-related complications, stent patency, patient survival rate and postoperative biochemical tests were investigated.
resultsAll the 47 patients tolerated well a total of 65 RFA procedures with self-expandable metal stents placed. The predominant disease was distal cholangiocarcinoma (16 of 47 cases). No procedure-related hemobilia or infections occurred. The main postablation complication was pain which could be controlled by analgesics. One patient suffered abdominal hemorrhage, diagnosed by blood test and abdominal ultrasonography and cured with conservative therapy. Significantly decreased TBIL and DBIL levels (P < 0.05) were observed on day 7 postoperatively. Stent patency was 149 days (15-281). Median survival was 181 days (15-495) from the time of the first RFA in each patient.
conclusionsPercutaneous intraluminal RFA combined with biliary stenting is a safe and feasible therapeutic option for unresectable extrahepatic malignant biliary obstruction. Multiple central prospective controlled trials are necessary for the long-term benefits of RFA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.